Vaccines (Jun 2024)

mRNA Vaccine for Alzheimer’s Disease: Pilot Study

  • Armine Hovakimyan,
  • Garri Chilingaryan,
  • Olga King,
  • Joia Kai Capocchi,
  • Jean Paul Chadarevian,
  • Hayk Davtyan,
  • Roman Kniazev,
  • Michael G. Agadjanyan,
  • Anahit Ghochikyan

DOI
https://doi.org/10.3390/vaccines12060659
Journal volume & issue
Vol. 12, no. 6
p. 659

Abstract

Read online

The escalating global healthcare challenge posed by Alzheimer’s Disease (AD) and compounded by the lack of effective treatments emphasizes the urgent need for innovative approaches to combat this devastating disease. Currently, passive and active immunotherapies remain the most promising strategy for AD. FDA-approved lecanemab significantly reduces Aβ aggregates from the brains of early AD patients administered biweekly with this humanized monoclonal antibody. Although the clinical benefits noted in these trials have been modest, researchers have emphasized the importance of preventive immunotherapy. Importantly, data from immunotherapy studies have shown that antibody concentrations in the periphery of vaccinated people should be sufficient for targeting Aβ in the CNS. To generate relatively high concentrations of antibodies in vaccinated people at risk of AD, we generated a universal vaccine platform, MultiTEP, and, based on it, developed a DNA vaccine, AV-1959D, targeting pathological Aβ, completed IND enabling studies, and initiated a Phase I clinical trial with early AD volunteers. Our current pilot study combined our advanced MultiTEP technology with a novel mRNA approach to develop an mRNA vaccine encapsulated in lipid-based nanoparticles (LNPs), AV-1959LR. Here, we report our initial findings on the immunogenicity of 1959LR in mice and non-human primates, comparing it with the immunogenicity of its DNA counterpart, AV-1959D.

Keywords